PMID: 11897978Mar 19, 2002Paper

Development of population pharmacokinetic models and optimal sampling times for ibuprofen tablet and suspension formulations in children with cystic fibrosis

Therapeutic Drug Monitoring
Paul BeringerC S Scott

Abstract

High-dose ibuprofen therapy has demonstrated to slow deterioration in pulmonary function in children with cystic fibrosis with mild lung disease. Therapeutic drug monitoring has been recommended to maintain peak concentrations within the range of 50 to 100 mg/L to ensure efficacy. Current methods for dosage individualization are based on dose proportionality using visual inspection of the peak concentration; however, because of interpatient variability in the absorption of the various formulations this method may result in incorrect assessments of the peak concentration achieved. Maximum a posteriori Bayesian analysis (MAP-B) has proven to be a useful and precise method of individualizing the dose of aminoglycosides but requires a description of the structural model. In this study we performed parametric population modeling analysis on plasma concentrations of ibuprofen after single doses of 20 to 30-mg/kg tablet or suspension in children with cystic fibrosis. Patients evaluated in this study were part of a single dose pharmacokinetic study that has been published previously. A one-compartment model with first order absorption and a lag time best described the data. The pharmacokinetic parameters differed significantly dependin...Continue Reading

References

Jun 1, 1991·The Journal of Pediatrics·M W KonstanP B Davis
Aug 1, 1981·Journal of Pharmacokinetics and Biopharmaceutics·L B Sheiner, S L Beal
Mar 30, 1995·The New England Journal of Medicine·M W KonstanP B Davis
Jul 18, 1996·The New England Journal of Medicine·B W Ramsey
Apr 30, 1999·Pharmacotherapy·D J MurryM M Sockrider

❮ Previous
Next ❯

Citations

Dec 13, 2003·Archives of Disease in Childhood·I ArranzE Ripoll
Aug 7, 2009·Malaria Journal·Julie A SimpsonStephen B Duffull
Feb 12, 2004·Clinical Pharmacokinetics·Emily E HanBertrand J Shapiro
Feb 19, 2008·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Jelena Parojcić, Owen I Corrigan
Jun 28, 2005·Pharmacotherapy·William A Prescott, Cary E Johnson
Mar 5, 2004·Paediatric Anaesthesia·Brian J Anderson
Nov 15, 2008·Pharmaceutical Statistics·Kayode OgungbenroLeon Aarons
Mar 9, 2011·Journal of Clinical Pharmacology·Hanbin LiDavid Kellstein
Mar 9, 2011·Therapeutic Drug Monitoring·A Franciscus van der MeerCees Neef

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.